Skip to content
value.today

CoLucid Pharmaceuticals, Inc.

🇺🇸 Durham, North Carolina, USAPharmaceuticalsFounded 2005
Total raised
$46 M
2 rounds on record
Latest round
$37 M
Jan 2015
First round on record
Jan 2009
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of CoLucid Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2015$37 MNo. 2$10 to $50 million

CoLucid Pharmaceuticals, Inc.: Raise no. 2, Jan 2015

Investors in this round

11 investors had bought by the notice of Jan 26, 2015: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for CoLucid Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$37 M of $37 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: New Series C Preferred Stock, and additional shares of Series A Preferred Stock and Series B Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arthur M. Pappas · Executive Officer, Director
  • Bernice C. Kuca · Executive Officer
  • Mathers P. Thomas · Executive Officer, Director
  • Nadia C. Rupniak · Executive Officer
  • Timothy C. Gupton · Executive Officer
  • Jesse I. Treu · Director
  • Luc C. Marengere · Director
  • Martin C. Edwards · Director
  • Richard J. Markham · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes conversion of indebtedness.”
  • On the use of proceeds: “No proceeds are proposed to be used for payment to such persons other than ordinary salary expenses that may be paid out of working capital.”

Signed by Timothy C. Gupton, Cfo. Source: SEC Form D, newest notice filed Jan 26, 2015. Read the notice at the SEC.

equitySEC
Jan 2009$9 MNo. 1$2 to $10 million

CoLucid Pharmaceuticals, Inc.: Raise no. 1, Jan 2009

Investors in this round

8 investors had bought by the notice of Jan 26, 2010: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 10 investors are named for CoLucid Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$9 M of $14 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arthur M Pappas · Executive Officer, Director
  • Daniel L Boeglin · Executive Officer
  • James F White · Executive Officer, Director
  • Nadia C Rupniak · Executive Officer
  • Timothy C Gupton · Executive Officer
  • Jesse I Treu · Director
  • Richard I Markham · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “No proceeds are proposed to be used for payment to such persons other than ordinary salary expenses that may be paid out of working capital.”

Signed by James F. White, President and CEO. Source: SEC Form D, newest notice filed Jan 26, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • CoLucid Pharmaceuticals, Inc. had no revenue when it filed its newest notice of a funding round (Jan 2015).

    SEC Form D (revenue range) · Jan 2015

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2015

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

10 named in official filings. Open an investor to see everything it has backed.

Investors in CoLucid Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
A.M. Pappas & Associates, LLCOthernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
A.M. Pappas Life Science Ventures III, L.P.Venture capitalnot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Care Capital III LLCFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Care Capital Investments III L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Care Capital Offshore Investments III LPFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Domain Partners VI, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
DP VI Associates, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Novo Holdings A/sFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
PV III CEO Fund, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
TVM Life Science Ventures VII L.P.Venture capitalnot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2015)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 11 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by CoLucid Pharmaceuticals, Inc.
NameRoleNamed in
Arthur M. PappasExecutive officerJan 2015
Bernice C. KucaExecutive officerJan 2015
Mathers P. ThomasExecutive officerJan 2015
Nadia C. RupniakExecutive officerJan 2015
Timothy C. GuptonExecutive officerJan 2015
Arthur M PappasExecutive officerJan 2010
Daniel L BoeglinExecutive officerJan 2010
James F WhiteExecutive officerJan 2010
Nadia C RupniakExecutive officerJan 2010
Timothy C GuptonExecutive officerJan 2010
Arthur M. PappasDirectorJan 2015
Jesse I. TreuDirectorJan 2015
Luc C. MarengereDirectorJan 2015
Martin C. EdwardsDirectorJan 2015
Mathers P. ThomasDirectorJan 2015
Richard J. MarkhamDirectorJan 2015
Arthur M PappasDirectorJan 2010
James F WhiteDirectorJan 2010
Jesse I TreuDirectorJan 2010
Richard I MarkhamDirectorJan 2010